INFLIXIMAB IN TREATMENT OF ACTIVE JUVENILE ARTHRITIS
https://doi.org/10.15690/vsp.v11i3.311
Abstract
The article includes the results of observation of patients with resistant forms of juvenile arthritis, who have received treatment with infliximab in the period of time since 2004 till 2011. The drug was administered to 41 patients: 19 with systemic juvenile idiopathic
arthritis, 6 with articulate form and 16 with juvenile spondiloarthritis. It was given intravenous (drop at a time), at first in dosage 3–5 mg/kg according to the scheme 0, 2, 6 and then every 8 weeks. The best efficacy was noted in juvenile spondiloarthritis and articulate form of juvenile idiopathic arthritis. By the 12 th month of the observation all the patients in these groups have achieved good results, corresponding with 70 % of improvement according to pediatric criteria of the American College of Rheumatologists. In patients with systemic arthritis a moderate positive effect was seen in first two months of treatment. By the 6th month the signs of disease have not significantly differ from those before Infliximab administration.
arthritis, 6 with articulate form and 16 with juvenile spondiloarthritis. It was given intravenous (drop at a time), at first in dosage 3–5 mg/kg according to the scheme 0, 2, 6 and then every 8 weeks. The best efficacy was noted in juvenile spondiloarthritis and articulate form of juvenile idiopathic arthritis. By the 12 th month of the observation all the patients in these groups have achieved good results, corresponding with 70 % of improvement according to pediatric criteria of the American College of Rheumatologists. In patients with systemic arthritis a moderate positive effect was seen in first two months of treatment. By the 6th month the signs of disease have not significantly differ from those before Infliximab administration.
About the Authors
E. S. Zholobova
I.M. Setchenov First Moscow State Medical University
Russian Federation
Zholobova Elena Spartakovna, PhD, professor of the Department of Child Diseases
Russian Federation
Zholobova Elena Spartakovna, PhD, professor of the Department of Child Diseases
O. Yu. Konopel'ko
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
D. V. Dagbaeva
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
A. V. Bunin
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
O. S. Rozvadovskaya
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
M. N. Nikolaeva
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
V. Ya. El'yashevich
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Cassidi J. T., Petty R. E. Textbook of Pediatric Rheumatology. W. B. Saunders Company. Toronto. 2002. 819 p.
2. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общей ред. А. А. Баранова. М.: ВЕДИ. 2007. 368 с.
3. Жолобова Е. С., Шахбазян И. Е., Улыбина О. В. и соавт. Ювенильный ревматоидный артрит. Руководство по детской ревматологии / под ред. Н. А. Геппе, Н. С. Подчерняевой, Г. А. Лыскиной. М.: ГЭОТАР-Медиа. 2011. С. 162–245.
4. Beutler B. A. The role of tumor necrosis factor in health and disease. J. Rheumatol. Suppl. 1999; 57: 16–21.
5. Lamot L., Bukovac L. T., Vidovic M. et al. The 'head-to-head' compa rison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2011; 29 (1): 131–139.
6. Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность лечения инфликсимабом у больных ювенильным ревматоидным артритом. Материалы Х Конгресса педиатров России. Вопросы современной педиатрии. 2006; 5 (2): 20–30.
7. Алексеева Е. И., Алексеева А. М., Бзарова Т. М. и соавт. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (1): 17–23.
8. Алексеева Е. И., Алексеева А. М., Валиева С. И. и соавт. Влияние инфликсимаба на клинические и лабораторные показатели активности при различных вариантах юношеского артрита. Вопросы современной педиатрии. 2008; 7: 42–54.
9. Козлова А. Л., Алексеева Е. И., Валиева С. И. и соавт. Эффективность инфликсимаба у больных ювенильным анкилозирующим спондилоартритом. Вопросы современной педиатрии. 2009; 8 (2): 20–26.
10. Gerloni V., Pontikaki I., Gattinara M. et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005; 52 (2): 548–553.
11. Никишина И. П., Родионовская С. Р., Шаповаленко и соавт. Инфликсимаб в терапии рефрактерных вариантов ювенильного артрита. Вопросы современной педиатрии. 2010; 9 (1): 142–149.
Review
For citations:
Zholobova E.S., Konopel'ko O.Yu., Dagbaeva D.V., Bunin A.V., Rozvadovskaya O.S., Nikolaeva M.N., El'yashevich V.Ya. INFLIXIMAB IN TREATMENT OF ACTIVE JUVENILE ARTHRITIS. Current Pediatrics. 2012;11(3):120-125. (In Russ.) https://doi.org/10.15690/vsp.v11i3.311
Views:
878
Email this article 
